{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "C",
          "alt": "R",
          "position": "418"
        },
        "variant_string_id": "PARK2 C418R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the ubiquitin ligase parkin account for most autosomal recessive forms of juvenile Parkinson’s disease (AR-JP). Parkin is associated with autosomal recessive juvenile forms of Parkinson’s disease and has been characterized as a ubiquitin ligase that acts as a negative modulator of apoptosis.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism where parkin, a ubiquitin ligase, acts as a negative modulator of apoptosis, which is relevant to the functional assay being described for this variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper examines the effect of parkin on p53 expression and activity, which is a well-established process in the field of Parkinson’s disease research.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used for this variant effectively models the disease pathogenesis/mechanism defined in Step 1, as the effect of parkin on p53 is directly related to the pathogenesis of Parkinson’s disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "judgment": "Yes",
          "reasoning": "The paper includes basic controls and replicates for the assays, as indicated by the description of multiple experiments performed in triplicate."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "judgment": "Yes",
          "reasoning": "The paper specifically examines the effect of the C418R mutation on parkin's ability to control p53, providing direct evidence for the variant's impact on the protein's function."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The C418R variant in parkin was found to abolish the parkin-mediated control of p53, both in vitro and in vivo, leading to a very strong pathogenic evidence strength rating according to ACMG guidelines."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "C",
          "alt": "R",
          "position": "441"
        },
        "variant_string_id": "PARK2 C441R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the ubiquitin ligase parkin account for most autosomal recessive forms of juvenile Parkinson’s disease (AR-JP). Parkin is associated with autosomal recessive juvenile forms of Parkinson’s disease and has been characterized as a ubiquitin ligase that acts as a negative modulator of apoptosis.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism where parkin, a ubiquitin ligase, acts as a negative modulator of apoptosis, which is relevant to the functional assay being described for this variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper examines the effect of parkin on p53 expression and activity, which is a well-established process in the field of Parkinson’s disease research.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used for this variant effectively models the disease pathogenesis/mechanism defined in Step 1, as the effect of parkin on p53 is directly related to the pathogenesis of Parkinson’s disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "judgment": "Yes",
          "reasoning": "The paper includes basic controls and replicates for the assays, as indicated by the description of multiple experiments performed in triplicate."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "judgment": "Yes",
          "reasoning": "The paper specifically examines the effect of the C441R mutation on parkin's ability to control p53, providing direct evidence for the variant's impact on the protein's function."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The C441R variant in parkin was found to abolish the parkin-mediated control of p53, both in vitro and in vivo, leading to a very strong pathogenic evidence strength rating according to ACMG guidelines."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "K",
          "alt": "N",
          "position": "161"
        },
        "variant_string_id": "PARK2 K161N"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the ubiquitin ligase parkin account for most autosomal recessive forms of juvenile Parkinson’s disease (AR-JP). Parkin is associated with autosomal recessive juvenile forms of Parkinson’s disease and has been characterized as a ubiquitin ligase that acts as a negative modulator of apoptosis.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism where parkin, a ubiquitin ligase, acts as a negative modulator of apoptosis, which is relevant to the functional assay being described for this variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper examines the effect of parkin on p53 expression and activity, which is a well-established process in the field of Parkinson’s disease research.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used for this variant effectively models the disease pathogenesis/mechanism defined in Step 1, as the effect of parkin on p53 is directly related to the pathogenesis of Parkinson’s disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "judgment": "Yes",
          "reasoning": "The paper includes basic controls and replicates for the assays, as indicated by the description of multiple experiments performed in triplicate."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "judgment": "Yes",
          "reasoning": "The paper specifically examines the effect of the K161N mutation on parkin's ability to control p53, providing direct evidence for the variant's impact on the protein's function."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The K161N variant in parkin was found to abolish the parkin-mediated control of p53, both in vitro and in vivo, leading to a very strong pathogenic evidence strength rating according to ACMG guidelines."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "256"
        },
        "variant_string_id": "PARK2 R256C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the ubiquitin ligase parkin account for most autosomal recessive forms of juvenile Parkinson’s disease (AR-JP). Parkin is associated with autosomal recessive juvenile forms of Parkinson’s disease and has been characterized as a ubiquitin ligase that acts as a negative modulator of apoptosis.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism where parkin, a ubiquitin ligase, acts as a negative modulator of apoptosis, which is relevant to the functional assay being described for this variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper examines the effect of parkin on p53 expression and activity, which is a well-established process in the field of Parkinson’s disease research.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used for this variant effectively models the disease pathogenesis/mechanism defined in Step 1, as the effect of parkin on p53 is directly related to the pathogenesis of Parkinson’s disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "judgment": "Yes",
          "reasoning": "The paper includes basic controls and replicates for the assays, as indicated by the description of multiple experiments performed in triplicate."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "judgment": "Yes",
          "reasoning": "The paper specifically examines the effect of the R256C mutation on parkin's ability to control p53, providing direct evidence for the variant's impact on the protein's function."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The R256C variant in parkin was found to abolish the parkin-mediated control of p53, both in vitro and in vivo, leading to a very strong pathogenic evidence strength rating according to ACMG guidelines."
    }
  ]
}